GlassScriptPhysician profile
Abraham Fridman
NPI 1205074945
$6,162.07
in general payments reported to CMS, 2019-2025
29 companies · $579 in 2025
The $579 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,616 · 2020: $215 · 2021: $204 · 2022: $152 · 2023: $29.86 · 2024: $365 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $975.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $974.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $3,223.39 | 2019 | |
| Intuitive Surgical, INC. | $995.37 | 2019-2020 | |
| Novo Nordisk INC | $713.48 | 2019-2025 | Wegovy |
| Currax Pharmaceuticals LLC | $215.74 | 2019-2025 | Contrave |
| Exact Sciences Corporation | $118.13 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $115.92 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Redhill Biopharma INC. | $75.29 | 2021-2024 | Talicia |
| Endo Pharmaceuticals INC. | $69.02 | 2019-2021 | |
| Intra-Sana Laboratories | $58.76 | 2021-2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Csl Behring | $57.45 | 2022 | |
| Amgen INC. | $53.13 | 2024 | Prolia, Evenity |
| Ethicon US, LLC | $48.19 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.78 | 2024-2025 | Xifaxan |
| Boston Scientific Corporation | $44.03 | 2020-2021 | |
| Portola Pharmaceuticals, LLC | $37.63 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.74 | 2024 | Jardiance |
| Apollo Endosurgery US INC | $29.10 | 2019 | |
| W. L. Gore & Associates, INC. | $27.00 | 2022-2024 | Gore Seamguard Bioabsorbable Staple Line Reinforce |
| Shield Therapeutics INC | $24.25 | 2024 | |
| Davol INC. | $24.19 | 2019 | |
| Xeris Pharmaceuticals, INC. | $23.50 | 2025 | Gvoke Hypopen |
| Lucid Diagnostics INC. | $19.73 | 2024 | |
| Vivus LLC | $19.31 | 2019 | |
| Teleflex LLC | $18.49 | 2020 | |
| Merck Sharp & Dohme LLC | $15.78 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Glaxosmithkline, LLC. | $15.51 | 2024 | Trelegy Ellipta |
| Nalpropion Pharmaceuticals LLC | $15.04 | 2019 | |
| Smith+Nephew, INC. | $14.91 | 2021 | |
| Abbott Laboratories | $12.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abraham Fridman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.